Skip to main content
. Author manuscript; available in PMC: 2016 Aug 10.
Published in final edited form as: J Med Chem. 2016 Apr 4;59(7):3471–3488. doi: 10.1021/acs.jmedchem.6b00085

Figure 8.

Figure 8

Western blot analysis of HEK cells overexpressing the I477N myocilin mutant and treated with 1 μM of indicated Grp94-selective inhibitors illustrating (A) myocilin degradation and (B) lack of AKT degradation and Hsp70 induction. Ratio of myocilin (C), AKT (D), and Hsp70 (E) normalized to actin for each compound. Vehicle = DMSO and 17-AAG = 17-(allylamino)-17-demethoxygeldanamycin (pan-Hsp90 N-terminal inhibitor).